Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Stryker Corporation's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $114.2B | |
|---|---|---|
| Revenue (ttm) | 25.8B | |
| Net income (ttm) | 3.7B | |
| EPS (ttm) | $9.65 | |
| Shares out | 383.6M | |
| P/E (trailing) | 31.5x | |
| P/E (forward) | 16.5x | |
| Dividend | $3.52 (1.16%) | |
| Volume | 1,512,185 | |
| Beta | 0.78 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.11B | $18.45B | $20.50B | $22.60B | $25.12B | +10.1% |
| Gross profit | $10.97B | $11.58B | $13.06B | $14.44B | $16.07B | +10.0% |
| Operating income | $2.58B | $2.84B | $3.89B | $3.69B | $4.89B | +17.3% |
| Net income | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B | +13.0% |
| EPS (diluted) | $5.21 | $6.17 | $8.25 | $7.76 | $8.40 | +12.7% |
| EBITDA | $3.61B | $4.02B | $5.06B | $6.01B | $6.31B | +15.0% |
| R&D | $1.24B | $1.45B | $1.39B | $1.47B | $1.62B | +7.1% |
| SG&A | $6.43B | $6.39B | $7.11B | $7.69B | $8.65B | +7.7% |
Recent company headlines from major financial publishers.
Accelerated hospital capital equipment spending, record Mako robotic placements in hospital and ASC settings, and rapid clearance of Peripheral Vascular backorders drive double-digit earnings compounding and accelerated operating margin expansion ahead of house expectations.
Stryker executes within its guided organic sales growth corridors, transitioning to steady high-single-digit revenue expansion through FY2030 supported by resilient reconstructive procedure volumes and steady operating margin progression.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.6% | $346 | $357 | $368 | $381 | $395 |
| 8.1% | $321 | $329 | $338 | $348 | $359 |
| 8.6% | $299 | $306 | $313 | $321 | $330 |
| 9.1% | $280 | $286 | $292 | $299 | $306 |
| 9.6% | $264 | $269 | $274 | $279 | $285 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
